Real-time disease monitoring predicts early relapse and refines conventional imaging in patients with DLBCL
      Monitoring lymphoma treatment has long relied on PET-CT scans, but these are imperfect. Circulating tumor DNA (ctDNA) offers a minimally invasive, highly specific way to track disease in real time. In our study, we explored how ctDNA can reshape response assessment in DLBCL.